AI/ML-based Discovery of Novel, Orally Bioavailable 5-HT2A Receptor Agonists Mimicking Psilocin for Unmet Mental Health Needs

Time: 4:20 pm
day: Conference Day One


  • The psychedelic psilocybin, a prodrug of Psilocin, has demonstrated rapid and lasting antidepressant efficacy after a single administration
  • Psilocin may promote neuroplasticity and alters the connectivity between different regions of the brain, which may promote alleviation of depressive symptoms
  • This presentation will highlight the use of an artificial intelligence (AI) – and machine learning (ML)-based drug design approach to discover novel 5-HT2A receptor agonists that show pharmacological effects consistent with psilocin, including antidepressant-like activity